The launch of Sovaldi the aday pill for hepatitis C is shaping up as the most successful ever The Food and Drug Administration approved the pill in December And then Gilead Sciences was off to the races The company said it sold  billion worth of Sovaldi in the quarter that ended March   The boffo number beat Wall Streets estimate for the quarter   Sovaldi is the first hepatitis C pill that doesnt have to be accompanied by   for some types of hepatitis Sovaldi has been found to be remarkably effective essentially curing  percent or more patients with a common form of hepatitis C in  weeks Sovaldis profile has the potential to transform the treatment of hepatitis C and the rapid uptake speaks to a significant unmet medical need Gilead CEO John Martin told analysts and investors during a Tuesday conference call But the price of the drug has drawn fire The predicted costs of the new oral antiviral agents are as breathtaking as their effectiveness said   in a recent issue of the   Costs alone cast a pall over the stunning success in achieving the longhopedfor goal of a safe and effective therapy for hepatitis C In December   a vice president at Gilead said the high price is fully justified We didnt really say We want to charge  a pill  Alton said Were just looking at what we think was a fair price for the value that were bringing into the health care system and to the patients In Tuesdays conference call analysts peppered Gilead management with questions about the companys talks with insurers about covering the treatment One approach to contain costs would limit the use of Sovaldi to patients with more advanced hepatitis C marked by significant scarring of the liver I do not believe its justified medically to prioritize and restrict the cure of hepatitis C It may be necessary economically said Norbert W Bischofberger Gileads head of research during the call The Centers for Disease Control and Prevention estimates that   in the US have chronic hepatitis C infections Most of them havent been diagnosed To make the case for Sovaldis price Gilead put together a chart of hepatitis C treatment costs for a variety of medicines A combination of Sovaldi a common form of interferon and the antiviral ribavirin would cost  for treatment that would last  weeks Other drug combinations that would take longer for treatment ranged from  to  One of the alternatives to Sovaldi is   made by Vertex Pharmaceuticals And it was Incivek approved by the FDA in  that held the record for the fastest launch   billion in the first year  until Sovaldi smashed it last month   from the industry watchers at EP Vantage